

Ryan Vandrey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/793348/publications.pdf>

Version: 2024-02-01

87
papers

4,285
citations

145106

33
h-index

139680

61
g-index

87
all docs

87
docs citations

87
times ranked

3733
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | The Long-Term, Prospective, Therapeutic Impact of Cannabis on Post-Traumatic Stress Disorder. <i>Cannabis and Cannabinoid Research</i> , 2022, 7, 214-223. | 1.5 | 13 |
| 2 | Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Yellow Oil in Healthy Participants. <i>Journal of Analytical Toxicology</i> , 2022, 46, 393-407. | 1.7 | 11 |
| 3 | Safety, Pharmacokinetics and Pharmacodynamics of Spectrum Red Softgels in Healthy Participants. <i>Journal of Analytical Toxicology</i> , 2022, 46, 528-539. | 1.7 | 9 |
| 4 | Urinary Pharmacokinetic Profile of Cannabidiol (CBD), δ^9 -Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. <i>Journal of Analytical Toxicology</i> , 2022, 46, 494-503. | 1.7 | 20 |
| 5 | The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use. <i>Addiction</i> , 2022, 117, 1510-1517. | 1.7 | 44 |
| 6 | Pharmacokinetic Profile of δ^9 -Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products. <i>Journal of Analytical Toxicology</i> , 2022, 46, 583-591. | 1.7 | 13 |
| 7 | The iCannToolkit: a tool to embrace measurement of medicinal and non-medical cannabis use across licit, illicit and cross-cultural settings. <i>Addiction</i> , 2022, , . | 1.7 | 3 |
| 8 | Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. <i>JAMA Network Open</i> , 2022, 5, e2211677. | 2.8 | 19 |
| 9 | Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2022, 46, 882-890. | 1.7 | 3 |
| 10 | Sex differences in the acute effects of oral and vaporized cannabis among healthy adults. <i>Addiction Biology</i> , 2021, 26, e12968. | 1.4 | 60 |
| 11 | A Cross-Sectional and Prospective Comparison of Medicinal Cannabis Users and Controls on Self-Reported Health. <i>Cannabis and Cannabinoid Research</i> , 2021, 6, 548-558. | 1.5 | 23 |
| 12 | An Evaluation of Potential Unintended Consequences of a Nicotine Product Standard: A Focus on Drinking History and Outcomes. <i>Nicotine and Tobacco Research</i> , 2021, 23, 1168-1175. | 1.4 | 7 |
| 13 | Cannabinoids for Agitation in Alzheimer's Disease. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 1253-1263. | 0.6 | 12 |
| 14 | The failings of <i>per se</i> limits to detect cannabis-induced driving impairment: Results from a simulated driving study. <i>Traffic Injury Prevention</i> , 2021, 22, 102-107. | 0.6 | 27 |
| 15 | Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. <i>Neuropsychopharmacology</i> , 2021, 46, 1451-1459. | 2.8 | 17 |
| 16 | Brain imaging of cannabinoid type 1 (CB ₁) receptors in women with cannabis use disorder and male and female healthy controls. <i>Addiction Biology</i> , 2021, 26, e13061. | 1.4 | 27 |
| 17 | Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis. <i>Journal of Psychopharmacology</i> , 2021, 35, 786-803. | 2.0 | 30 |
| 18 | Refraining from use diminishes cannabis-associated epigenetic changes in human sperm. <i>Environmental Epigenetics</i> , 2021, 7, dvab009. | 0.9 | 41 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Antidepressant and Anxiolytic Effects of Medicinal Cannabis Use in an Observational Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 729800. | 1.3 | 30 |
| 20 | Cross-sectional and longitudinal evaluation of cannabidiol (CBD) product use and health among people with epilepsy. <i>Epilepsy and Behavior</i> , 2021, 122, 108205. | 0.9 | 8 |
| 21 | Feasibility and acceptability of using smartphone-based EMA to assess patterns of prescription opioid and medical cannabis use among individuals with chronic pain. <i>Internet Interventions</i> , 2021, 26, 100460. | 1.4 | 9 |
| 22 | Study rationale and baseline data for pilot trial of dronabinol adjunctive treatment of agitation in Alzheimer's dementia (THC-AD). <i>International Psychogeriatrics</i> , 2021, , 1-6. | 0.6 | 5 |
| 23 | Urinary Excretion Profile of 11-Nor-9-Carboxy- Δ^9 -Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users. <i>Journal of Analytical Toxicology</i> , 2020, 44, 1-14. | 1.7 | 14 |
| 24 | Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. <i>Journal of Psychopharmacology</i> , 2020, 34, 197-210. | 2.0 | 10 |
| 25 | Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis. <i>Journal of Analytical Toxicology</i> , 2020, 44, 109-125. | 1.7 | 37 |
| 26 | Cigarette Smokers Versus Cousers of Cannabis and Cigarettes: Exposure to Toxicants. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1383-1389. | 1.4 | 19 |
| 27 | Measuring the temporal association between cannabis and tobacco use among Co-using young adults using ecological momentary assessment. <i>Addictive Behaviors</i> , 2020, 104, 106250. | 1.7 | 11 |
| 28 | Cannabinoid effects on responses to quantitative sensory testing among individuals with and without clinical pain: a systematic review. <i>Pain</i> , 2020, 161, 244-260. | 2.0 | 10 |
| 29 | Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. <i>Pharmacology Biochemistry and Behavior</i> , 2020, 199, 173059. | 1.3 | 28 |
| 30 | The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. <i>Drug and Alcohol Dependence</i> , 2020, 212, 107993. | 1.6 | 49 |
| 31 | Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ^9 -Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females. <i>Journal of Analytical Toxicology</i> , 2020, 44, 661-671. | 1.7 | 30 |
| 32 | Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. <i>Drug and Alcohol Dependence</i> , 2020, 211, 107937. | 1.6 | 80 |
| 33 | Pharmacodynamic dose effects of oral cannabis ingestion in healthy adults who infrequently use cannabis. <i>Drug and Alcohol Dependence</i> , 2020, 211, 107969. | 1.6 | 47 |
| 34 | Priority Considerations for Medicinal Cannabis-Related Research. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 139-157. | 1.5 | 21 |
| 35 | Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects. <i>Addiction</i> , 2019, 114, 1824-1833. | 1.7 | 4 |
| 36 | Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation. <i>PLoS ONE</i> , 2019, 14, e0215853. | 1.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724. | 1.5 | 130 |
| 38 | Changing landscape of cannabis: novel products, formulations, and methods of administration. <i>Current Opinion in Psychology</i> , 2019, 30, 98-102. | 2.5 | 148 |
| 39 | Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers. <i>Nicotine and Tobacco Research</i> , 2019, 21, S63-S72. | 1.4 | 17 |
| 40 | The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings. <i>Nicotine and Tobacco Research</i> , 2019, 21, S73-S80. | 1.4 | 17 |
| 41 | Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder. <i>Drug and Alcohol Dependence</i> , 2019, 194, 500-517. | 1.6 | 39 |
| 42 | Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. <i>Journal of Analytical Toxicology</i> , 2019, 43, 233-258. | 1.7 | 74 |
| 43 | Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein. <i>PLoS ONE</i> , 2019, 14, e0210104. | 1.1 | 20 |
| 44 | “Hallucinations” Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. <i>Cannabis and Cannabinoid Research</i> , 2018, 3, 85-93. | 1.5 | 24 |
| 45 | Pharmacokinetic Characterization of 11-nor-9-carboxy- Δ^9 -tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults. <i>Journal of Analytical Toxicology</i> , 2018, 42, 232-247. | 1.7 | 16 |
| 46 | The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration. <i>Drug and Alcohol Dependence</i> , 2018, 187, 254-260. | 1.6 | 25 |
| 47 | Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks. <i>Tobacco Control</i> , 2018, 27, 420-426. | 1.8 | 25 |
| 48 | Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis. <i>JAMA Network Open</i> , 2018, 1, e184841. | 2.8 | 161 |
| 49 | The cannabis conundrum: steering policy and medicine with insufficient data. <i>International Review of Psychiatry</i> , 2018, 30, 181-182. | 1.4 | 9 |
| 50 | Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches. <i>International Review of Psychiatry</i> , 2018, 30, 277-284. | 1.4 | 47 |
| 51 | Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 880. | 3.8 | 113 |
| 52 | Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.. <i>Experimental and Clinical Psychopharmacology</i> , 2018, 26, 223-232. | 1.3 | 10 |
| 53 | Cannabis Withdrawal: a Review of Neurobiological Mechanisms and Sex Differences. <i>Current Addiction Reports</i> , 2017, 4, 75-81. | 1.6 | 66 |
| 54 | Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes. <i>Journal of Analytical Toxicology</i> , 2017, 41, 83-99. | 1.7 | 156 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Morning administration of oral methamphetamine dose-dependently disrupts nighttime sleep in recreational stimulant users. <i>Drug and Alcohol Dependence</i> , 2017, 178, 291-295. | 1.6 | 20 |
| 56 | Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes. <i>Tobacco Control</i> , 2017, 26, e43-e48. | 1.8 | 17 |
| 57 | Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. <i>Addictive Behaviors</i> , 2017, 72, 14-20. | 1.7 | 105 |
| 58 | Labeling Accuracy of Cannabidiol Extracts Sold Online. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1708. | 3.8 | 406 |
| 59 | Response to varying the nicotine content of cigarettes in vulnerable populations: an initial experimental examination of acute effects. <i>Psychopharmacology</i> , 2017, 234, 89-98. | 1.5 | 32 |
| 60 | Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms. <i>Nicotine and Tobacco Research</i> , 2017, 19, 59-67. | 1.4 | 49 |
| 61 | Sleep continuity, architecture and quality among treatment-seeking cannabis users: An in-home, unattended polysomnographic study.. <i>Experimental and Clinical Psychopharmacology</i> , 2017, 25, 295-302. | 1.3 | 19 |
| 62 | Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes. <i>Addiction</i> , 2016, 111, 2208-2216. | 1.7 | 44 |
| 63 | Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use. <i>Drug and Alcohol Dependence</i> , 2016, 167, 228-232. | 1.6 | 23 |
| 64 | A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users. <i>Drug and Alcohol Dependence</i> , 2016, 167, 199-206. | 1.6 | 23 |
| 65 | Training and Practices of Cannabis Dispensary Staff. <i>Cannabis and Cannabinoid Research</i> , 2016, 1, 244-251. | 1.5 | 75 |
| 66 | The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 606-615. | 1.4 | 22 |
| 67 | Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation. <i>Nicotine and Tobacco Research</i> , 2016, 18, 1171-1179. | 1.4 | 11 |
| 68 | Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.. <i>Experimental and Clinical Psychopharmacology</i> , 2015, 23, 415-421. | 1.3 | 92 |
| 69 | Nonsmoker Exposure to Secondhand Cannabis Smoke. III. Oral Fluid and Blood Drug Concentrations and Corresponding Subjective Effects. <i>Journal of Analytical Toxicology</i> , 2015, 39, 497-509. | 1.7 | 45 |
| 70 | Non-smoker exposure to secondhand cannabis smoke II: Effect of room ventilation on the physiological, subjective, and behavioral/cognitive effects. <i>Drug and Alcohol Dependence</i> , 2015, 151, 194-202. | 1.6 | 59 |
| 71 | Cannabinoid Dose and Label Accuracy in Edible Medical Cannabis Products. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 2491. | 3.8 | 281 |
| 72 | Non-Smoker Exposure to Secondhand Cannabis Smoke. I. Urine Screening and Confirmation Results. <i>Journal of Analytical Toxicology</i> , 2015, 39, 1-12. | 1.7 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and <i>Ad libitum</i> Cannabis Smoking in Chronic Frequent Users. <i>Journal of Analytical Toxicology</i> , 2015, 39, 580-587. | 1.7 | 40 |
| 74 | Oral fluid cannabinoids in chronic frequent cannabis smokers during <i>ad libitum</i> cannabis smoking. <i>Drug Testing and Analysis</i> , 2015, 7, 494-501. | 1.6 | 14 |
| 75 | Mobile App-Delivered Cognitive Behavioral Therapy for Insomnia: Feasibility and Initial Efficacy Among Veterans With Cannabis Use Disorders. <i>JMIR Research Protocols</i> , 2015, 4, e87. | 0.5 | 57 |
| 76 | Using cannabis to help you sleep: Heightened frequency of medical cannabis use among those with PTSD. <i>Drug and Alcohol Dependence</i> , 2014, 136, 162-165. | 1.6 | 162 |
| 77 | Interactions between disordered sleep, post-traumatic stress disorder, and substance use disorders. <i>International Review of Psychiatry</i> , 2014, 26, 237-247. | 1.4 | 60 |
| 78 | Cannabis use history and characteristics of quit attempts: A comparison study of treatment-seeking and non-treatment-seeking cannabis users.. <i>Experimental and Clinical Psychopharmacology</i> , 2014, 22, 517-523. | 1.3 | 13 |
| 79 | The dose effects of short-term dronabinol (oral THC) maintenance in daily cannabis users. <i>Drug and Alcohol Dependence</i> , 2013, 128, 64-70. | 1.6 | 91 |
| 80 | Novel Drugs of Abuse: A Snapshot of an Evolving Marketplace. <i>Adolescent Psychiatry (Hilversum)</i> , 2013, 10, 21-30. | 0.1 | 21 |
| 81 | A survey study to characterize use of Spice products (synthetic cannabinoids). <i>Drug and Alcohol Dependence</i> , 2012, 120, 238-241. | 1.6 | 239 |
| 82 | Sleep disturbance and the effects of extended-release zolpidem during cannabis withdrawal. <i>Drug and Alcohol Dependence</i> , 2011, 117, 38-44. | 1.6 | 100 |
| 83 | Pay-for-performance in a community substance abuse clinic. <i>Journal of Substance Abuse Treatment</i> , 2011, 41, 193-200. | 1.5 | 19 |
| 84 | Increased Blood Pressure After Abrupt Cessation of Daily Cannabis Use. <i>Journal of Addiction Medicine</i> , 2011, 5, 16-20. | 1.4 | 30 |
| 85 | Pharmacotherapy for Cannabis Dependence. <i>CNS Drugs</i> , 2009, 23, 543-553. | 2.7 | 98 |
| 86 | Contingency management in cocaine abusers: A dose-effect comparison of goods-based versus cash-based incentives.. <i>Experimental and Clinical Psychopharmacology</i> , 2007, 15, 338-343. | 1.3 | 62 |
| 87 | The iCannToolkit: A consensus-based, flexible framework for measuring contemporary cannabis use. <i>Addiction</i> , 0, , . | 1.7 | 1 |